Article

Areas Of Growth For Oral-Dose Outsourcing

Source: ISR Reports

By Kate Hammeke, VP of Market Research, Industry Standard Research (ISR) @ISRreports

The long history and market dominance of oral dosage forms have made this category of drug product a good candidate for outsourced manufacturing. And, according to respondents* who participated in Industry Standard Research’s 2019 Oral Dosage Forms survey, there are no signs of oral-dose outsourcing letting up. In fact, across all sponsor groups, respondents predict increases in the proportion of oral-dose manufacturing that is outsourced. For clinical trial manufacturing, the increase averaged 6 percentage points, climbing from 54 percent to 60 percent outsourced, and for commercial manufacturing, the increase averaged 8 percentage points, rising from 57 percent to 65 percent outsourced.

Not only is the proportion of outsourcing predicted to increase, so is the number of oral-dose products in sponsors’ pipelines, which means that even if outsourcing percentages remained static, CMOs could anticipate increased demand because sponsors expect to have more oral-dose products in their portfolios five years from now. Some of the same characteristics that helped the oral dose earn its valued position in healthcare — ease of accurate dosing and patient-friendly delivery format — will continue to contribute to its popularity, but so will use of newer technologies such as modified release combined with advances in the dosage form, like multilayer tablets.

VIEW THE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Pharmaceutical Online